{"id":"insulin-lispro-mm","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL1201538","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin lispro is a recombinant human insulin analog created by reversing two amino acids (lysine and proline) at positions 28 and 29 of the B chain. This modification reduces self-association and allows faster absorption from subcutaneous injection sites compared to regular human insulin. Once absorbed, it binds to insulin receptors on muscle and adipose tissue to facilitate glucose transport and metabolism, lowering blood glucose levels.","oneSentence":"Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:13.258Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05067270","phase":"PHASE1","title":"A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-10-22","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT01120444","phase":"PHASE1, PHASE2","title":"Study on the Effects on Blood Glucose Following Intradermal and Subcutaneous Dosing of Insulin in Diabetic Patients","status":"COMPLETED","sponsor":"Becton, Dickinson and Company","startDate":"2010-04","conditions":"Diabetes","enrollment":20},{"nctId":"NCT00393705","phase":"PHASE4","title":"Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":302},{"nctId":"NCT00377858","phase":"PHASE4","title":"Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-08","conditions":"Diabetes Mellitus, Type 2","enrollment":484}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mid Mix","Humalog"],"phase":"marketed","status":"active","brandName":"insulin lispro MM","genericName":"insulin lispro MM","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin lispro MM is a protein-based insulin receptor agonist used to treat diabetes. It is classified as an agonist and is indicated for the treatment of diabetes mellitus, type 1 and type 2.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}